title: Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets.
abstract: Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) continue to be identified and with a lack of effective clinical treatment and no preventative strategies, treatment using convalescent plasma or monoclonal antibodies (mAbs) is a potential quick route to an intervention. Passive immunotherapy via either convalescent plasma or mAbs has proven to be effective for other infectious agents. Following infection with MERS-CoV, common marmosets were treated with high titer hyperimmune plasma or the mAb m336, at 6 and 48 h post inoculation. Both treatments reduced signs of clinical disease, but reduction in viral loads in the respiratory tract were only found in the hyperimmune plasma group. A decrease in gross pathology was found only in the mAb-treated group, but no histological differences were observed between treated and control animals. While both hyperimmune plasma and the m336 treatments reduced the severity of disease in the common marmoset, neither treatment resulted in full protection against disease.
authors.affiliation: Virus Ecology Unit, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
authors.forename: Neeltje
authors.initials: N
authors.lastname: van Doremalen
authors.affiliation: Disease Modeling and Transmission, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
authors.forename: Darryl
authors.initials: D
authors.lastname: Falzarano
authors.affiliation: Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
authors.forename: Tianlei
authors.initials: T
authors.lastname: Ying
authors.affiliation: Disease Modeling and Transmission, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
authors.forename: Emmie
authors.initials: E
authors.lastname: de Wit
authors.affiliation: Virus Ecology Unit, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
authors.forename: Trenton
authors.initials: T
authors.lastname: Bushmaker
authors.affiliation: Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
authors.forename: Friederike
authors.initials: F
authors.lastname: Feldmann
authors.affiliation: Disease Modeling and Transmission, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA; Department of Microbiology, University of Washington, Seattle, WA, USA.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Okumura
authors.affiliation: Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
authors.forename: Yanping
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
authors.forename: Dana P
authors.initials: DP
authors.lastname: Scott
authors.affiliation: Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Hanley
authors.affiliation: Disease Modeling and Transmission, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
authors.forename: Heinz
authors.initials: H
authors.lastname: Feldmann
authors.affiliation: Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
authors.forename: Dimiter S
authors.initials: DS
authors.lastname: Dimitrov
authors.affiliation: Virus Ecology Unit, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA. Electronic address: munstervj@niaid.nih.gov.
authors.forename: Vincent J
authors.initials: VJ
authors.lastname: Munster
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000276:immunology / Q000627:therapeutic use; D002144:Callithrix / Q000821:virology*; D002460:Cell Line; D018352:Coronavirus Infections / Q000188:drug therapy* / Q000662:veterinary* / Q000821:virology; D004195:Disease Models, Animal; D005260:Female; D007116:Immunization, Passive / Q000379:methods* / Q000662:veterinary*; D007150:Immunohistochemistry; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology / Q000821:virology; D008297:Male; D065207:Middle East Respiratory Syndrome Coronavirus / Q000472:pathogenicity*; D008992:Monkey Diseases / Q000188:drug therapy / Q000473:pathology / Q000821:virology; D011859:Radiography; D012137:Respiratory System / Q000000981:diagnostic imaging / Q000473:pathology / Q000821:virology; D019562:Viral Load / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral
keywords: Common marmoset; Hyperimmune plasma; Immunotherapy; MERS-CoV; Monoclonal antibodies; Treatment